- Citations, last 5 years
- 203
- Works, last 5 years
- 17
- h-index
- 21
- Scientists listed
- 0
- Grants since 2016
- 8
Grants received
2024–2025 · research · R41
Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Mengqian Chen · Senex Biotechnology (United States) · funded by National Institutes of Health
2022–2024 · grant · PCRP
Developing Mediator Kinase Inhibitor for Castration-Refractory Prostate Cancer
George Wilding · Senex Biotechnology (United States) · funded by Congressionally Directed Medical Research Programs
2022–2024 · research · R43
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition
Eugenia V Broude · Senex Biotechnology (United States) · funded by National Institutes of Health
2017–2019 · research · R43
CDK8/19 inhibitor for the treatment of HER2+ breast cancer
Eugenia V Broude · Senex Biotechnology (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Targeting CDK8 for the treatment of vein graft failure
Donald C. Porter · Senex Biotechnology (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Enhancing cytarabine efficacy in leukemia through CDK8/19 inhibition
Donald C. Porter · Senex Biotechnology (United States) · funded by National Institutes of Health
2015–2022 · research · R44
CDK8/19 inhibitors for therapy of advanced prostate cancer
Mengqian Chen · Senex Biotechnology (United States) · funded by National Institutes of Health
2015–2023 · research · R44
CDK8/19 inhibitors for therapy of advanced prostate cancer
Mengqian Chen · Senex Biotechnology (United States) · funded by National Institutes of Health